Eli Lilly vs Merck & Co

Eli Lilly (LLY), health care, and Merck & Co (MRK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Eli Lilly is worth $1.26T on the stock market and Merck & Co $354.4B: Eli Lilly is valued at 3.6 times as much. Eli Lilly trades at 45.9 times earnings and Merck & Co at 145. Over the past year Eli Lilly's share price has moved +39.0% and Merck & Co's +49.8%.

Key facts

Eli Lilly market value
$1.26T
Merck & Co market value
$354.4B
Eli Lilly P/E
45.9
Merck & Co P/E
145
Eli Lilly revenue
$65.2BFY to 2025-12-31
Merck & Co revenue
$65BFY to 2025-12-31
Superinvestors holding both
12

Market values as of .

Eli Lilly vs Merck & Co: every measure side by side
Measure Eli Lilly Merck & Co
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$1.26Thigher$354.4Blower
Revenue$65.2Bhigher$65Blower
Earnings$20.6Bhigher$18.3Blower
Employees50,000lower73,000higher
Total assets$112.5Blower$136.9Bhigher
Valuation
P/E45.9lower145higher
P/S19.3higher5.5lower
P/B31.3higher7.9lower
Dividend yield0.47%lower2.33%higher
Profitability
Operating margin——
Balance sheet
Net assets$26.5Blower$52.6Bhigher
Total liabilities$85.9Bhigher$84.2Blower
Total debt$42.5Blower$49.3Bhigher
Cash on hand$7.3Blower$14.6Bhigher
Price change
Today-1.22%lower-0.48%higher
1 year+39.0%lower+49.8%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Eli Lilly / Merck & Co). Who owns LLY · Who owns MRK

Further comparisons

Learn

Questions and answers

Which is bigger, Eli Lilly or Merck & Co?

By market value, Eli Lilly is the larger: $1.26T against $354.4B for Merck & Co. By revenue in its latest fiscal year, Eli Lilly is the larger: $65.2B against $65B for Merck & Co.

Which has the higher P/E ratio?

Merck & Co: 145, against 45.9 for Eli Lilly. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher dividend yield?

Merck & Co: 2.33%, against 0.47% for Eli Lilly. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Merck & Co: $49.3B, against $42.5B for Eli Lilly. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Eli Lilly and Merck & Co?

In their latest 13F filings, Mairs & Power team, Jeremy Grantham (co-founder), Ken Fisher, Rajiv Jain, Ken Griffin, Temasek, Brandon Haley, Cliff Asness, David Shaw (founder), Murray Stahl, Dodge & Cox team and Bill Nygren hold both.

Cite this page

Funkfolio, “Eli Lilly vs Merck & Co”, data as of 17 November 2026. https://funkfolio.com/compare/lly-vs-mrk

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.